Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: A meta-analysis of randomized controlled trials

Gynecologic and Obstetric Investigation

Volumn 75, Issue 4, 2013, Pages 255-262

  Sun, Zheng ^a   Hao, Yanqing ^a   Zhang, Min ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Adverse events; Desvenlafaxine; Hot flashes; Meta analysis

Indexed keywords

DESVENLAFAXINE; PLACEBO;

AROUSAL; ARTICLE; ASTHENIA; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MENOPAUSE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; XEROSTOMIA;

EID: 84878858514     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000348564     Document Type: Article

References (30)

1. Freedman RR, Norton D, Woodward S, Cornélissen G: Core body temperature and circadian rhythm of hot flashes in menopaus-al women. J Clin Endocrinol Metab 1995; 80: 2354-2358.
2. Bachmann GA: Vasomotor flushes in meno-pausal women. Am J Obstet Gynecol 1999; 180:S312-S316.
3. Ziaei S, Kazemnejad A, Zareai M: The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest 2007; 64:204-207.
4. Politi MC, Schleinitz MD, Col NF: Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008; 23:1507-1513.
5. Igarashi M, Saito H, Morioka Y, et al: Stress vulnerability and climacteric symptoms: life events, coping behavior, and severity of symptoms. Gynecol Obstet Invest 2000; 49: 170-178.
6. North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242-255.
7. Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen and combined oes-trogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4:CD002978.
8. Nelson HD: Commonly used types of post-menopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291: 1610-1620.
9. Lobo RA, McCormick W, Singer F, Roy S: De-po-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984; 63:1-5.
10. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
11. Wyrwich KW, Spratt DI, Gass M, et al: Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008; 15:698-705.
12. Archer DF, Dupont CM, Constantine GD, et al: Desvenlafaxine for the treatment of vaso-motor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009; 200: 238 e1-238 e10.
13. Archer DF, Seidman L, Constantine GD, et al: A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009; 200:172 e1-e10.
14. Gallagher JC, Strzinek RA, Cheng RF, et al: The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health (Larchmt) 2012; 21:188-198.
15. Pinkerton JV, Constantine G, Hwang E, et al: Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013; 20:28-37.
16. Cheng RJ, Dupont C, Archer DF, et al: Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric 2013; 16:17-27.
17. Pinkerton JV, Archer DF, Guico-Pabia CJ, et al: Maintenance of the efficacy of desvenlafax-ine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause 2013; 20:38-46.
18. Archer DF, Pinkerton JV, Guico-Pabia CJ, et al: Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 2013; 20:47-56.
19. Bouchard P, Panay N, de Villiers TJ, et al: Randomized placebo-and active-controlled study of desvenlafaxine for menopausal vaso-motor symptoms. Climacteric 2012; 15:12-20.
20. Greene JG: Constructing a standard climacteric scale. Maturitas 1998; 29:25-31.
21. Higgins JPT, Green S: The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2009.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analy-ses. BMJ 2003; 327:557-560.
23. Lau J, Ioannidis JP, Terrin N, et al: The case of the misleading funnel plot. BMJ 2006; 333: 597-600.
24. Speroff L, Gass M, Constantine G, et al: Efficacy and tolerability of desvenlafaxine succi-nate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Ob-stet Gynecol 2008; 111:77-87.
25. Pinkerton JV, Constantine G, Hwang E, et al: Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013; 20:28-37.
26. European Medicines Agency EMEA: Withdrawal assessment report for Pristiqs. Available at: http://wwwemeaeuropaeu/human-docs/PDFs/EPAR/pristiqs/H-794-WARpdf (accessed 02.09.08).
27. Sproule BA, Hazra M, Pollock BG: Desvenla-faxine succinate for major depressive disorder. Drugs Today (Barc) 2008; 44:475-487.
28. Umland EM, Falconieri L: Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health 2012; 4:305-319.
29. Deecher DC, Dorries K: Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmeno-pause life stages. Arch Womens Ment Health 2007; 10:247-257.
30. Simo A, Stevens RE, Ayres SA, Phelps KV: Perimenopausal women in estrogen vasomo-tor trials: contribution to placebo effect and efficacy outcome. Climacteric 2001; 4:19-27.